The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1143 articles
Prescription drug coupons can seem like a straightforward way to save money. However, for individuals with health insurance, these discounts can come with unexpected financial implications. This article delves into the nuances of manufacturer-sponsored coupons, their impact on insurance plans, and how to make informed decisions at the pharmacy counter.
Achieving sustainable weight loss is a journey, not a race. This comprehensive guide offers expert advice on nutrition, exercise, and mindset to help you build healthy habits for life.
Eli Lilly's monumental $4.5 billion investment in its Indiana facilities signals a significant ramp-up in production for groundbreaking GLP-1 agonists like Mounjaro and Zepbound, alongside future weight loss and cardiometabolic disease treatments. This expansion is poised to meet surging global demand and solidify Lilly's position at the forefront of pharmaceutical innovation.
CVS Health exceeded earnings expectations, but what does this mean for patients using GLP-1 medications like Ozempic or Wegovy? We break down the financial news and its real-world implications for your healthcare coverage.
A groundbreaking NIH-funded study reveals that emerging GLP-1 weight-loss drugs, including oral options like orforglipron, work by targeting a specific brain reward pathway, distinct from their appetite-suppressing effects. This discovery opens new avenues for understanding and treating conditions beyond weight management.
The massive adoption of GLP-1 receptor agonists for weight management is creating a significant ripple effect across the food industry, specifically driving an intense surge in demand for high-quality, muscle-preserving protein sources like whey. Dairy producers are scrambling to meet this new market reality.
New research suggests a connection between GLP-1 medications and temporary hair loss. Discover what this means for users of drugs like Ozempic, Wegovy, and Mounjaro, and how to navigate this common side effect.
A man's harrowing experience with extreme diarrhea after overdosing on an experimental GLP-1 drug, retatrutide, serves as a stark reminder of the risks associated with obtaining and using unapproved medications outside of medical supervision. This article delves into the case, the science behind these powerful weight loss drugs, and the importance of regulated healthcare.
GLP-1 receptor agonists are powerful tools for managing diabetes and obesity, but understanding their potential interactions with other medications is crucial for patient safety and treatment efficacy.
